Huons' flagship eye drop product entered the Saudi Arabia market, signaling the company’s expansion of its overseas business.

Huons said Tuesday that Saudi Food and Drug Authority (SFDA) approved Clasgen Eye Drops, a treatment for dry eye syndrome, and it would begin exporting the product. It is the first domestic eye drop to win regulatory permission in the Middle East country.

The Saudi Food and Drug Authority (SFDA) has permitted Huons to market its product, Clasgen Eye Drops, for dry eye syndrome. (Huons)

Clasgen Eye Drops is a monotherapy for dry eye syndrome that increases tear secretion in patients with suppressed tear production.

Clasgen Eye Drops is a modified drug of Restasis, a classic eye dryness treatment. The new product is characterized by easy use as the fluid is colorless and transparent through nano-particularization, and does not need to be shaken before application.

Saudi Arabia's dry eye therapy market is dominated by Restasis, which is worth about 3 billion won ($2.53 million), according to Huons. The company added that it is meaningful for its Clasgen Eye Drops, a modified drug that has improved Restasis's inconvenient aspect, to obtain SFDA permission and to enter the local market.

Amman Pharma, a leading company specializing in eye drops in the Middle East and Africa, will distribute Clasgen Eye Drops in the local market.

Huons plans to target the local pharmaceutical market by promoting various eye treatments, including nanocomposite eye drops and ophthalmic preparations (High-Eye injection), with Amman Pharma into Saudi Arabia.

"We are pleased to become the first Korean eye drop maker to advance to Saudi Arabia, which accounts for a large proportion of the Middle East pharmaceutical market," Huons CEO Uhm Ki-ahn said. "The recent SFDA approval proved our products’ quality and efficacy. We will further expand to the Middle East and other markets."

shim531@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>